Literature DB >> 17143814

The Pneumonia Severity Index score: time to move to a prospective study of patients with community-acquired pneumonia who are discharged from emergency departments to be managed on an ambulatory basis.

Thomas J Marrie.   

Abstract

Entities:  

Mesh:

Year:  2006        PMID: 17143814     DOI: 10.1086/509333

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  6 in total

1.  The value of prognostic indices for pneumonia.

Authors:  Jennie Johnstone; Sumit R Majumdar; Thomas J Marrie
Journal:  Curr Infect Dis Rep       Date:  2008-05       Impact factor: 3.725

2.  Population-based cohort study of outpatients with pneumonia: rationale, design and baseline characteristics.

Authors:  Dean T Eurich; Sumit R Majumdar; Thomas J Marrie
Journal:  BMC Infect Dis       Date:  2012-06-18       Impact factor: 3.090

3.  Enhancement of CURB65 score with proadrenomedullin (CURB65-A) for outcome prediction in lower respiratory tract infections: derivation of a clinical algorithm.

Authors:  Werner C Albrich; Frank Dusemund; Kristina Rüegger; Mirjam Christ-Crain; Werner Zimmerli; Thomas Bregenzer; Sarosh Irani; Ulrich Buergi; Barbara Reutlinger; Beat Mueller; Philipp Schuetz
Journal:  BMC Infect Dis       Date:  2011-05-03       Impact factor: 3.090

4.  Application and comparison of scoring indices to predict outcomes in patients with healthcare-associated pneumonia.

Authors:  Wen-Feng Fang; Kuang-Yao Yang; Chieh-Liang Wu; Chong-Jen Yu; Chang-Wen Chen; Chih-Yen Tu; Meng-Chih Lin
Journal:  Crit Care       Date:  2011-01-19       Impact factor: 9.097

Review 5.  Pneumonia in the emergency department.

Authors:  Joseph F Plouffe; Daniel R Martin
Journal:  Emerg Med Clin North Am       Date:  2008-05       Impact factor: 2.264

6.  Inpatient treatment of community-acquired pneumonias with integrative medicine.

Authors:  Ulrich Geyer; Klas Diederich; Maria Kusserow; Andreas Laubersheimer; Klaus Kramer
Journal:  Evid Based Complement Alternat Med       Date:  2013-05-22       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.